| Paul D Ledoux, MD | |
|
1800 Medical Center Pkwy, Suite 330, Murfreesboro, TN 37129-2567 | |
| (615) 396-4464 | |
| (615) 396-6748 |
| Full Name | Paul D Ledoux |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 41 Years |
| Location | 1800 Medical Center Pkwy, Murfreesboro, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457305716 | NPI | - | NPPES |
| 0093018 | Other | TN | BCBS |
| 3021207 | Medicaid | TN | |
| 050011509 | Other | TN | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD15605 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Thomas Rutherford Hospital | Murfreesboro, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Murfreesboro Anesthesia Group, P.a. | 9335038868 | 55 |
News Archive
Coeliac disease is a chronic, immunological disease that is manifested as intolerance to gluten proteins present in wheat, rye and barley. This intolerance leads to an inflammatory reaction in the small intestine that hampers the absorption of nutrients. The only treatment is a strict, life-long, gluten-free diet.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent Office (USPTO) has allowed a patent (Application No. 10/560,336) for the Woppmann et al. patent series, entitled "Double-stranded ribonucleic acid with increased effectiveness in an organism." The newly allowed patent includes 31 claims broadly covering compositions and methods, including pharmaceutical compositions, for small interfering RNAs (siRNAs), the molecules that mediate RNAi.
Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.
Cardiovascular disease (CVD) is the leading cause of death in Europe, killing an estimated 4.3 million people each year. Results from a large pan-European study announced today indicate that many of these deaths could be avoided if at-risk patients received better preventative care.
A pilot study has found that pregnant women who have suffered from depression or bipolar disorder (i.e. both mania and depression) recognize babies' faces and how babies laugh or cry, differently to healthy controls.
› Verified 3 days ago
| Entity Name | Murfreesboro Anesthesia Group, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912959867 PECOS PAC ID: 9335038868 Enrollment ID: O20040312001032 |
News Archive
Coeliac disease is a chronic, immunological disease that is manifested as intolerance to gluten proteins present in wheat, rye and barley. This intolerance leads to an inflammatory reaction in the small intestine that hampers the absorption of nutrients. The only treatment is a strict, life-long, gluten-free diet.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent Office (USPTO) has allowed a patent (Application No. 10/560,336) for the Woppmann et al. patent series, entitled "Double-stranded ribonucleic acid with increased effectiveness in an organism." The newly allowed patent includes 31 claims broadly covering compositions and methods, including pharmaceutical compositions, for small interfering RNAs (siRNAs), the molecules that mediate RNAi.
Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.
Cardiovascular disease (CVD) is the leading cause of death in Europe, killing an estimated 4.3 million people each year. Results from a large pan-European study announced today indicate that many of these deaths could be avoided if at-risk patients received better preventative care.
A pilot study has found that pregnant women who have suffered from depression or bipolar disorder (i.e. both mania and depression) recognize babies' faces and how babies laugh or cry, differently to healthy controls.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul D Ledoux, MD Po Box 1252, Murfreesboro, TN 37133-1252 Ph: (615) 396-4464 | Paul D Ledoux, MD 1800 Medical Center Pkwy, Suite 330, Murfreesboro, TN 37129-2567 Ph: (615) 396-4464 |
News Archive
Coeliac disease is a chronic, immunological disease that is manifested as intolerance to gluten proteins present in wheat, rye and barley. This intolerance leads to an inflammatory reaction in the small intestine that hampers the absorption of nutrients. The only treatment is a strict, life-long, gluten-free diet.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent Office (USPTO) has allowed a patent (Application No. 10/560,336) for the Woppmann et al. patent series, entitled "Double-stranded ribonucleic acid with increased effectiveness in an organism." The newly allowed patent includes 31 claims broadly covering compositions and methods, including pharmaceutical compositions, for small interfering RNAs (siRNAs), the molecules that mediate RNAi.
Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.
Cardiovascular disease (CVD) is the leading cause of death in Europe, killing an estimated 4.3 million people each year. Results from a large pan-European study announced today indicate that many of these deaths could be avoided if at-risk patients received better preventative care.
A pilot study has found that pregnant women who have suffered from depression or bipolar disorder (i.e. both mania and depression) recognize babies' faces and how babies laugh or cry, differently to healthy controls.
› Verified 3 days ago
Eric Young, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1272 Garrison Dr, Murfreesboro, TN 37129 Phone: 161-589-3448 | |
Dr. Stephanie Petrina Noack, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1272 Garrison Dr, Murfreesboro, TN 37129 Phone: 615-893-4480 | |
Dr. Melissa Lynn Mckittrick, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 3400 Lebanon Rd, Murfreesboro, TN 37129 Phone: 615-225-2522 | |
Gregory Bryan Terry, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1800 Medical Center Pkwy, Suite 330, Murfreesboro, TN 37129 Phone: 615-396-4464 Fax: 615-396-6748 | |
Kenneth F Caissie, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1800 Medical Center Pkwy, Suite 330, Murfreesboro, TN 37129 Phone: 615-396-4464 Fax: 615-396-6748 | |
Andrew M Wright, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1800 Medical Center Pkwy, Suite 330, Murfreesboro, TN 37129 Phone: 615-396-4464 Fax: 615-396-6748 | |
Shyam A Jha, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 528 N University St, Murfreesboro, TN 37130 Phone: 615-968-7727 Fax: 615-467-8587 |